Qiming Venture Partners

Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

LongBio Pharma is a biotechnology company focused on developing treatments for patients with complement and allergy-related diseases within the autoimmune field. The company aims to improve patient outcomes by providing affordable and high-quality biomedicines. Through its innovative platform, LongBio Pharma works to bring its therapeutic solutions to both domestic and international markets, enabling healthcare professionals to offer enhanced treatment options to their patients.

Chenzhang Bio is a biotechnology developer specializing in stem cell storage and treatment technology. focusing on stem cell storage and treatment technologies, company's research and commercialization, enhancing its R&D team and promoting clinical application of stem cell treatment technology

CSR Biotech is a biological research company that specializes in the development and manufacturing of super-resolution imaging instruments for living cells. The company focuses on creating and deploying advanced imaging technology, offering a range of services including customized cell sample generation, high-throughput detection, imaging studies, and image post-processing with quantitative analysis. By providing these specialized tools and services, CSR Biotech aims to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby contributing to advancements in the field of biotechnology.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.

LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Simaixu Biotechnology is a biopharmaceutical firm that develop small molecule drugs for cancer, and chronic diseases with new technologies

Novamab is a biotechnology company specializing in the development of novel nanobodies, a type of single-domain antibody with unique therapeutic advantages. With over 15 years of experience in nanobody research and development, the company's team of pioneers in this field has established platforms to maximize the potential of nanobodies. Novamab focuses on creating innovative drug formulations such as inhaled macromolecular drugs, albumin nanobody long-acting therapies, and nanobody double-antibody combinations. Their primary goal is to address unmet clinical needs by improving administration methods and reducing treatment cycles for major chronic diseases like cancer, autoimmune disorders, and cardiovascular conditions.

Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China

GenEditBio is a biotechnology company dedicated to developing innovative gene editing therapies aimed at addressing unmet medical needs in the treatment of genetic diseases. The company focuses on the research and development of advanced in vivo gene editing tools and effective delivery systems. Through its efforts, GenEditBio seeks to provide curative solutions that leverage gene editing technology to improve patient outcomes and address the challenges posed by various genetic disorders.

CureGenetics is a biotechnology company focused on advancing innovative medicines and molecular diagnostics through the application of gene editing technologies. The company specializes in the research and development of solutions aimed at the treatment of cancers and genetic diseases. CureGenetics is dedicated to creating next-generation therapies that enhance patient outcomes by leveraging cutting-edge techniques in gene editing and delivery platforms. Through its efforts, the company aims to contribute significantly to the field of personalized medicine and improve treatment options for complex health conditions.

Emulate, Inc. is a biotechnology company specializing in organs-on-chips technology that emulates human biology to enhance the understanding of diseases, medicines, chemicals, and food impacts on human health. The company develops organ-chips that replicate normal organ functions as well as various disease states, primarily targeting the lung, intestine, liver, and skin. Emulate's innovative human emulation system provides researchers with advanced in vitro models that offer more precise and detailed predictions of human responses compared to traditional experimental methods, such as cell culture or animal testing. The company serves a diverse range of markets, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic research. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. before rebranding in July 2014.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

PRCXI Biotechnology is a biotech company that provides bioinformatics and automation solutions for life science and the manufacturing of analytical instruments.

Prime Lifescience is a developer of a big data platform tailored for the life sciences sector. The company focuses on creating a health lifecycle big data collaboration network through digital technology innovation and the extensive application of artificial intelligence. Prime Lifescience offers a digital smart health community, an intelligent clinical research accelerator, and a live big data platform. These offerings aim to enhance digital clinical research and foster a comprehensive medical solutions environment, ultimately benefiting the healthcare sector through improved data-driven insights and collaboration.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

CSR Biotech is a biological research company that specializes in the development and manufacturing of super-resolution imaging instruments for living cells. The company focuses on creating and deploying advanced imaging technology, offering a range of services including customized cell sample generation, high-throughput detection, imaging studies, and image post-processing with quantitative analysis. By providing these specialized tools and services, CSR Biotech aims to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby contributing to advancements in the field of biotechnology.

Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China

BayOmics is a high-tech enterprise specializing in the commercial development and application of proteomics research. The company utilizes integrated automated proteomics technology to perform functional proteome analysis and facilitate the discovery of new drug targets. By focusing on targeted drug research and development using micro-clinical samples, BayOmics aims to provide crucial technical support to the medical industry. This support is particularly geared towards the development of treatments for critical illnesses, including cancer and other significant diseases.

LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.

Ailomics Therapeutics, established in 2022 with headquarters in Shanghai, China, specializes in developing novel drugs for treating immune diseases and tumors. The company employs a computational biology platform to analyze multi-omics patient data, aiming to uncover new drug targets and mechanisms driving disease progression.

CuroVax, established in 2011 and headquartered in Changzhou City, China, specializes in vaccine development and production. The company offers a range of vaccines, including a freeze-dried rabies vaccine for human use and an influenza virus split vaccine. CuroVax employs a dual approach of independent development and collaborative research, supported by multiple technology platforms such as large-scale mammalian cell culture and mRNA vaccine development. It provides biotechnology and microbiology services, focusing on improving health and medical industry standards.

Complete Omics is a company focused on the development of multi-omics diagnostics for early disease detection, particularly in cancer. The firm specializes in creating personalized diagnosis and treatment platforms that leverage advanced technologies across various omics fields. With patented innovations, Complete Omics offers precision companion diagnostics that enhance the ability to conduct sensitive and specific health surveillance tests. By enabling researchers and pharmaceutical companies to utilize these sophisticated tools, Complete Omics aims to improve diagnosis and treatment outcomes in the field of oncology.

Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Allorion Therapeutics is a small molecule therapeutic development company specializing in the treatment of cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, Allorion focuses on creating mutant selective and isoform-specific drugs through innovative methods targeting established medical challenges. By concentrating on enhancing drug efficacy and preventing resistance in patients, the company aims to improve therapeutic outcomes in these critical areas of healthcare.

Insyce creates equipment and apparatus for science. Its business strives to provide tools and technology for bio labs that monitor the environment to deliver accurate data and speedy chemical analysis while keeping lab costs down for their clients. It is dedicated to providing upper biological separation equipment and chemical analysis tools for global clients, cutting down on client operating expenses, and adding value for clients.

Biotree Technology is a high-tech enterprise that specializes in the application, consulting, and development of advanced research technologies within the life sciences sector. Focusing on mass spectrometry and metabolomics, the company provides comprehensive solutions for early detection and analysis in China. With a strong core team experienced in metabolomics, Biotree Technology offers services in scientific research, health testing, and industrial testing. The company is recognized for its innovation in metabolomics products and technology, holding several patents in the field. It has established itself as a leader in metabolomics detection and analysis, maintaining steady growth and profitability over the years. Through its biotechnological testing and consulting services, Biotree Technology assists clients in testing product quality and conducting various biotechnological research projects.

Bio-Link is a drug development company founded in 2001 and headquartered in Shanghai, China. It specializes in providing bioprocessing solutions for the life science industry, including the development and manufacturing of key process equipment and consumables. Bio-Link's offerings include technologies for vaccines, antibody drugs, cell therapy, gene therapy, and various biologics. The company focuses on upstream cell culture, disposable dispensing reservoirs, and downstream processes such as chromatography and ultrafiltration. By delivering innovative products and services, Bio-Link aims to enhance the efficiency, safety, and competitiveness of the biopharmaceutical supply chain. Additionally, the company explores wearable technology solutions for elderly care, further diversifying its portfolio.

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

BayOmics is a high-tech enterprise specializing in the commercial development and application of proteomics research. The company utilizes integrated automated proteomics technology to perform functional proteome analysis and facilitate the discovery of new drug targets. By focusing on targeted drug research and development using micro-clinical samples, BayOmics aims to provide crucial technical support to the medical industry. This support is particularly geared towards the development of treatments for critical illnesses, including cancer and other significant diseases.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.

Core Medical (Beijing) Co., Ltd. is a contract research organization (CRO) founded in 2013 and based in Beijing, China. The company specializes in clinical professional services focused on new technologies and innovative products within the cardiovascular sector. Core Medical offers a range of services, including animal testing, type testing, First-in-Man (FIM) studies, human studies, and statistics and data management for clinical research. By providing these services, Core Medical helps companies in the cardiovascular field evaluate and validate their products, facilitating advancements in medical technology.

CSR Biotech is a biological research company that specializes in the development and manufacturing of super-resolution imaging instruments for living cells. The company focuses on creating and deploying advanced imaging technology, offering a range of services including customized cell sample generation, high-throughput detection, imaging studies, and image post-processing with quantitative analysis. By providing these specialized tools and services, CSR Biotech aims to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby contributing to advancements in the field of biotechnology.

Ailomics Therapeutics, established in 2022 with headquarters in Shanghai, China, specializes in developing novel drugs for treating immune diseases and tumors. The company employs a computational biology platform to analyze multi-omics patient data, aiming to uncover new drug targets and mechanisms driving disease progression.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

Biotree Technology is a high-tech enterprise that specializes in the application, consulting, and development of advanced research technologies within the life sciences sector. Focusing on mass spectrometry and metabolomics, the company provides comprehensive solutions for early detection and analysis in China. With a strong core team experienced in metabolomics, Biotree Technology offers services in scientific research, health testing, and industrial testing. The company is recognized for its innovation in metabolomics products and technology, holding several patents in the field. It has established itself as a leader in metabolomics detection and analysis, maintaining steady growth and profitability over the years. Through its biotechnological testing and consulting services, Biotree Technology assists clients in testing product quality and conducting various biotechnological research projects.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

RiboX Therapeutics is a biotech company that focuses on discovery and development of fully engineered circular RNA therapeutics.

LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China

M20 Genomics is a life science and technology company focused on advancing single-cell sequencing technology and its applications. The company aims to establish itself as a global leader in next-generation single-cell technology for disease diagnosis and treatment. Its innovative single-cell sequencing platform is capable of detecting nearly 10,000 genes from individual cells or nuclei in various sample types, including fresh, frozen, and formalin-fixed paraffin-embedded specimens. This technology enables researchers to enhance the efficiency of their studies, particularly in bacterial research, by providing comprehensive data through full-length RNA sequencing.

LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.

Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.

Curie.Bio, founded in 2022 and based in Boston, Massachusetts, is a venture capital firm that specializes in seed-stage investments. The firm focuses on early-stage therapeutics companies, aiming to support innovative solutions in the life sciences sector. As a Registered Investment Adviser, Curie.Bio is dedicated to fostering growth and development in the biotechnology field by partnering with founders and providing the necessary resources to help advance their ventures.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Prime Lifescience is a developer of a big data platform tailored for the life sciences sector. The company focuses on creating a health lifecycle big data collaboration network through digital technology innovation and the extensive application of artificial intelligence. Prime Lifescience offers a digital smart health community, an intelligent clinical research accelerator, and a live big data platform. These offerings aim to enhance digital clinical research and foster a comprehensive medical solutions environment, ultimately benefiting the healthcare sector through improved data-driven insights and collaboration.

Ceptur Therapeutics is focused on developing innovative genetic medicines for patients with unmet medical needs. The company utilizes its proprietary U1 Adaptor technology to achieve non-genotoxic, long-lasting silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and has potential applications in cancer treatment, allowing healthcare providers to offer new therapeutic options for various cancer types. Through its advancements, Ceptur aims to improve patient outcomes by providing effective solutions for difficult-to-treat conditions.

Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

CureGenetics is a biotechnology company focused on advancing innovative medicines and molecular diagnostics through the application of gene editing technologies. The company specializes in the research and development of solutions aimed at the treatment of cancers and genetic diseases. CureGenetics is dedicated to creating next-generation therapies that enhance patient outcomes by leveraging cutting-edge techniques in gene editing and delivery platforms. Through its efforts, the company aims to contribute significantly to the field of personalized medicine and improve treatment options for complex health conditions.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Allorion Therapeutics is a small molecule therapeutic development company specializing in the treatment of cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, Allorion focuses on creating mutant selective and isoform-specific drugs through innovative methods targeting established medical challenges. By concentrating on enhancing drug efficacy and preventing resistance in patients, the company aims to improve therapeutic outcomes in these critical areas of healthcare.

Tripod Preclinical Research is a Contract Research Organization that specializes in preclinical research services tailored for the biopharmaceutical industry. The company offers a comprehensive range of services, including nonhuman primate disease models, pharmacological efficacy assessments, early drug evaluations, and GLP toxicology. Tripod is committed to supporting global pharmaceutical companies, research and development enterprises, and medical device manufacturers in the evaluation of new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Additionally, the organization provides technology support in areas such as translational medicine, clinical trials, biological analysis, and the management of biological sample banks, ensuring that its clients have the necessary resources to advance their research and development efforts effectively.

Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2014. It specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical applications. The company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing essential therapeutic resources to patients globally. Through its innovative approach, Platelet BioGenesis is contributing to advancements in biotechnology and the field of transfusion medicine.

Okeanos Technology specializes in the custom synthesis and production of specialized chemical biological reagents and pharmaceutical intermediates tailored for the life sciences sector. The company offers a diverse range of products, including modified nucleotides, unnatural amino acids, heterocycles, as well as fluorescent and labeling reagents. Okeanos serves prominent pharmaceutical companies, delivering high-quality chemical compounds and intermediates that support various applications in research and development. Renowned for its commitment to quality and innovation, Okeanos has established a strong reputation among its clients in the pharmaceutical industry.

Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on designing and developing novel oral therapeutics to treat chronic diseases with high unmet need. Utilizing advanced computational and structure-based technology, the company creates life-changing medicines by integrating cutting-edge advancements in computational chemistry and molecular interaction visualization. Its pipeline includes GSBR-1290, an oral glucagon-like-peptide-1 receptor agonist for type-2 diabetes mellitus and obesity, as well as ANPA-0073 and LTSE-2578 targeting pulmonary and cardiovascular diseases respectively. The company's team, with deep experience in complex biological targets and structure-based drug design, aims to deliver efficacious and safe treatments with broad commercial potential.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

Genevide is a biotech company established in 2019 and based in Suzhou, Jiangsu, China. The company focuses on gene research and development, specifically addressing challenges in nucleic acid detection. Genevide has developed a molecular enzyme cycle screening platform that includes enzyme-mediated one-step sample processing technology and enzyme-mediated double exponential amplification nucleic acid detection technology. These innovations aim to enhance the accessibility and efficiency of nucleic acid detection for researchers.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.

Berry Oncology specializes in developing genetic diagnostic solutions for early detection and mid-to-late stage monitoring of various malignant tumors. Their offerings span from companion diagnostics to response monitoring and prognosis prediction for both targeted and immune therapies, aiming to enhance cancer prevention and tumor diagnosis globally. The company's primary mission is to facilitate early diagnosis and treatment of all tumors, ensuring precise care for patients. Berry Oncology aspires to become a global leader in early screening and diagnosis of tumors, particularly in China's tumor gene testing market.

Health Biotech is a research and development firm focused on precision medicine through the application of mass spectrometry technology. The company specializes in creating comprehensive detection solutions that include tools, equipment, and reagent consumables. Its innovative technology employs liquid chromatography-mass spectrometry to facilitate the early diagnosis, treatment, and monitoring of Alzheimer's disease. By quantitatively detecting specific biomarkers, such as "ipilin," Health Biotech enables healthcare professionals to assess Alzheimer's risk and provide targeted interventions aimed at delaying disease onset and enhancing cognitive function in patients. Through its commitment to advancing mass spectrometry applications, Health Biotech strives to deliver reliable services and improve patient outcomes in the realm of neurological health.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines utilizing its proprietary virus-like particle (VLP) platform technology. This innovative approach allows for the multivalent, particle-based display of complex viral antigens, which is aimed at generating broad and durable immune responses. Icosavax focuses primarily on life-threatening respiratory diseases, with its lead vaccine candidate, IVX-121, targeting respiratory syncytial virus (RSV) in older adults. The company's pipeline also includes candidates for human metapneumovirus (hMPV) and SARS-CoV-2, reflecting its commitment to advancing vaccine solutions for infectious diseases.

Basecamp Bio is a cell and gene therapy research and development company that develops cell and gene therapies, regenerative medicine, and immunotherapies.

Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and manufacturing of innovative immuno-oncology therapies. Founded in 2016 by a team of experienced professionals from leading pharmaceutical companies, Abbisko is dedicated to developing small molecule inhibitors, including ABSK011 and ABSK021, for the treatment of hepatocellular carcinoma, as well as CSF1R for solid tumors. In addition to oncology, the company is engaged in developing therapeutics for various conditions, including cancer, liver diseases, diabetes, metabolic disorders, viral infections, and central nervous system diseases.

LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Asieris Pharmaceuticals Co. Ltd. is a biotechnology company based in Taizhou, China, founded in 2010. The company is dedicated to the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. By focusing on oncology and infectious diseases, Asieris Pharmaceuticals seeks to develop innovative therapies that meet the medical needs of patients both in China and globally.

Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression for organ transplant recipients. The company's leading product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all chronic immunosuppression therapy within twelve months post-transplant. In addition to its applications in organ transplantation, Talaris’s technology facilitates the safe use of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, reducing the associated toxicity and risks of traditional methods. Founded in 1988 and originally named Regenerex, Inc., Talaris Therapeutics rebranded in March 2019. The company is headquartered in Louisville, Kentucky, with an additional office in Wellesley, Massachusetts.

MEDx is a company specializing in precision medicine solutions aimed at enhancing clinical development. Founded in 2013 and headquartered in Suzhou, Jiangsu, MEDx employs translational science to advance diagnostic technologies related to nucleic acids and proteins. Its comprehensive services include biomarker development, Companion Diagnostics, Point-of-Care development, clinical testing, and the commercialization of medical products. By focusing on individualized treatment, MEDx seeks to improve patient outcomes through its innovative approaches in the healthcare sector.

InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company has developed a range of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Among its notable products is D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in creating targeted immuno-oncology therapies that can be used in combination with existing treatments, such as PD-1 antibodies, to address various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with extensive experience in drug discovery at major pharmaceutical companies, InventisBio aims to provide effective therapies for significant health challenges.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and manufacturing of innovative immuno-oncology therapies. Founded in 2016 by a team of experienced professionals from leading pharmaceutical companies, Abbisko is dedicated to developing small molecule inhibitors, including ABSK011 and ABSK021, for the treatment of hepatocellular carcinoma, as well as CSF1R for solid tumors. In addition to oncology, the company is engaged in developing therapeutics for various conditions, including cancer, liver diseases, diabetes, metabolic disorders, viral infections, and central nervous system diseases.

CureGenetics is a biotechnology company focused on advancing innovative medicines and molecular diagnostics through the application of gene editing technologies. The company specializes in the research and development of solutions aimed at the treatment of cancers and genetic diseases. CureGenetics is dedicated to creating next-generation therapies that enhance patient outcomes by leveraging cutting-edge techniques in gene editing and delivery platforms. Through its efforts, the company aims to contribute significantly to the field of personalized medicine and improve treatment options for complex health conditions.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on designing and developing novel oral therapeutics to treat chronic diseases with high unmet need. Utilizing advanced computational and structure-based technology, the company creates life-changing medicines by integrating cutting-edge advancements in computational chemistry and molecular interaction visualization. Its pipeline includes GSBR-1290, an oral glucagon-like-peptide-1 receptor agonist for type-2 diabetes mellitus and obesity, as well as ANPA-0073 and LTSE-2578 targeting pulmonary and cardiovascular diseases respectively. The company's team, with deep experience in complex biological targets and structure-based drug design, aims to deliver efficacious and safe treatments with broad commercial potential.

Berry Genomics is a biotechnology company focused on the development and commercialization of genomic technologies for life sciences and clinical applications. The company specializes in next generation sequencing (NGS) tests aimed at detecting genetic diseases and cancers throughout various life stages, from preconception to adulthood. In addition to its testing services, Berry Genomics offers gene sequencing detection equipment, contributing to advancements in genetic research and diagnostics. Through its innovative approach, the company plays a significant role in the evolving field of genomics.

Berry Oncology specializes in developing genetic diagnostic solutions for early detection and mid-to-late stage monitoring of various malignant tumors. Their offerings span from companion diagnostics to response monitoring and prognosis prediction for both targeted and immune therapies, aiming to enhance cancer prevention and tumor diagnosis globally. The company's primary mission is to facilitate early diagnosis and treatment of all tumors, ensuring precise care for patients. Berry Oncology aspires to become a global leader in early screening and diagnosis of tumors, particularly in China's tumor gene testing market.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines utilizing its proprietary virus-like particle (VLP) platform technology. This innovative approach allows for the multivalent, particle-based display of complex viral antigens, which is aimed at generating broad and durable immune responses. Icosavax focuses primarily on life-threatening respiratory diseases, with its lead vaccine candidate, IVX-121, targeting respiratory syncytial virus (RSV) in older adults. The company's pipeline also includes candidates for human metapneumovirus (hMPV) and SARS-CoV-2, reflecting its commitment to advancing vaccine solutions for infectious diseases.

Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2014. It specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical applications. The company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing essential therapeutic resources to patients globally. Through its innovative approach, Platelet BioGenesis is contributing to advancements in biotechnology and the field of transfusion medicine.

Shenzhen Tisenc Medical Devices Co., Ltd., established in 2015, is a Sino-foreign joint venture based in Shenzhen, Guangdong. The company specializes in the development, manufacturing, and global sales of chemiluminescence immunology systems and advanced diagnostic solutions. Tisenc focuses on creating automatic chemiluminescent analyzers and supporting diagnostic reagents, which are essential in the field of medical diagnostics and point-of-care testing. With over 16,000 square meters dedicated to research and development labs, a GMP factory, and an instrument manufacturing facility, Tisenc maintains full intellectual property rights for its products and technologies, ensuring independence in its research and production processes.

Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression for organ transplant recipients. The company's leading product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all chronic immunosuppression therapy within twelve months post-transplant. In addition to its applications in organ transplantation, Talaris’s technology facilitates the safe use of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, reducing the associated toxicity and risks of traditional methods. Founded in 1988 and originally named Regenerex, Inc., Talaris Therapeutics rebranded in March 2019. The company is headquartered in Louisville, Kentucky, with an additional office in Wellesley, Massachusetts.